DOS方案治疗进展期胃癌患者围手术期40例

DOS Chemotherapy for Treating Advanced Gastric Cancer in 40 Cases of Perioperative Patients

目的探讨多西他赛、奥沙利铂联合替吉奥(DOS)的化学治疗(简称化疗)方案对进展期胃癌患者围手术期的影响。方法将收治的进展期胃癌患者80例随机分为对照组和观察组,各40例。对照组给予表阿霉素、顺铂和5-氟尿嘧啶(ECF)方案,观察组给予DOS方案,3周为1个疗程,两组均治疗3个疗程后行手术治疗。结果观察组术中出血量以及术后并发症总发生率显著低于对照组(P<0.05)。观察组R0,R1切除率分别为62.50%和37.50%,显著高于对照组的55.00%和30.00%(P<0.05);观察组R2切除率为0,显著低于对照组的15.00%(P<0.05)。观察组总有效率为62.50%,高于对照组的47.50%(P<0.05)。观察组总不良反应发生率明显低于对照组(P<0.05)。结论 DOS化疗方案对进展期胃癌患者围手术期具有一定积极影响,能显著减少术中出血量及术后并发症,且近期疗效好,不良反应相对较少。

Objective To investigate the effect of DOS chemotheraPy in treating PerioPerative Patients with advanced gastric cancer. Methods 80 cases of Patients with advanced gastric cancer from June 2012 to January 2014 were randomly divided into the control grouP and the observation grouP, 40 cases in each grouP. The control grouP received ePirubicin, cisPlatin and ECF regimen, and the ob-servation grouP received DOS regimen. 1 treatment course was 3 weeks, and the Patients received surgery after 3 courses of treat-ment. Results The blood loss and the overall incidence of PostoPerative comPlications of the observation grouP were significantly lower than those of the control grouP （ P 〈 0. 05 ）; the R0, R1 resection rates of the observation grouP were 62. 50% and 37. 50%, which were significantly higher than 55. 00% and 30. 00% of the control grouP （ P 〈 0. 05 ）;the R2 resection rate of the observation grouP was 0, which was significantly lower than 15. 00% of the control grouP （ P 〈 0. 05 ） . The total effective rate of the observation grouP was 62. 50%, which was significantly higher than 37. 50% of the control grouP （ P 〈 0. 05 ） . The total occurrence rate of adverse reac-tions of the observation grouP was significantly lower than the control grouP （ P 〈 0. 05 ） . Conclusion DOS chemotheraPy for PerioPera-tive Patients with advanced gastric cancer has certain Positive effect;it can significantly reduce blood loss and PostoPerative comPlica-tions in Patients with good short-term effect and relatively few adverse reactions.